David L. Scott
About
In The Last Decade
David L. Scott
406 papers receiving 19.1k citations
Hit Papers
Peers
Comparison fields: 5 of 211
- Rheumatology 8.9k
- Molecular Biology 4.5k
- Hematology 3.6k
- Immunology 2.7k
- Surgery 2.0k
Countries citing papers authored by David L. Scott
This map shows the geographic impact of David L. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Scott more than expected).
Fields of papers citing papers by David L. Scott
This network shows the impact of papers produced by David L. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Scott. The network helps show where David L. Scott may publish in the future.
Co-authorship network of co-authors of David L. Scott
This figure shows the co-authorship network connecting the top 25 collaborators of David L. Scott. A scholar is included among the top collaborators of David L. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Scott. David L. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 7 | |
| 3 | 1 | |
| 4 | 8 | |
| 5 | Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; Results from a Randomised Controlled Phase III Trial of Treatment Effectiveness | 3 |
| 6 | The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis breakdown → | 360 |
| 7 | Current limitations in the management of cardiovascular risk in rheumatoid arthritis. | 17 |
| 8 | Treat-to-Target in Rheumatoid Arthritis: Clinical and PharmacoEconomic Considerations | 3 |
| 9 | 233 | |
| 10 | 27 | |
| 11 | INTRODUCING CATS HAS NOT REDUCED RHEUMATOLOGY OUTPATIENT ACTIVITY: EXPERIENCE FROM AN INNER CITY ENVIRONMENT | 1 |
| 12 | PREDICTING REMISSION IN TRIAL OF INTENSIVE THERAPY IN EARLY RA: HAQ AND GENDER ARE KEY FACTORS | 1 |
| 13 | CLASSIFICATION CRITERIA FOR IDIOPATHIC INFLAMMATORY MYOSITIS: COMPARISON OF THE PERFORMANCE OF ACCEPTED CRITERIA | 1 |
| 14 | Comparative systematic review of TNF-inhibitors and intensive DMARD regimens in RA suggests similar efficacy | 1 |
| 15 | "A window of opportunity" in early rheumatoid arthritis: Sustained effect of step-down prednisolone on joint damage | 8 |
| 16 | Tumor necrosis factor inhibitors for rheumatoid arthritis - Reply | 0 |
| 17 | Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. | 267 |
| 18 | Guidelines for the diagnosis, investigation and management of osteoarthritis of the hip and knee. Report of a Joint Working Group of the British Society for Rheumatology and the Research Unit of the Royal College of Physicians. | 45 |
| 19 | 1 | |
| 20 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.